NCT05746208 2026-03-17
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
University of California, San Francisco
Phase 2 Recruiting
Clinical Trials
5 trialsNCT02402920 2026-03-10
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT06232564 2026-01-14
PELICAN
Imperial College London
Phase 2 Active not recruiting
NCT03457948 2025-09-03
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
University of California, San Francisco
Phase 2 Active not recruiting
NCT03190213 2021-06-22
Pembro NEC
University of Utah
Phase 2 Terminated